- Investor's Business Daily•14 hours ago
Celgene stock lifted Friday after unveiling drugs in testing that could tack on $3 billion to $4 billion in sales, RBC says.
- Investopedia•20 hours ago
Biotech funds are trading near rally highs, but two popular blue chip components are struggling, a foretelling weakness that could end the sector's recovery.
- Investor's Business Daily•2 days ago
A California ballot initiative requiring the state's Medicaid arm to buy drugs at comparable prices to what the VA pays could backfire, RBC says.
Celgene Corporation (CELG)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||104.21 x 200|
|Ask||104.80 x 200|
|Day's Range||102.70 - 105.24|
|52wk Range||93.05 - 128.39|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||44.17|
|Avg Vol (3m)||4,171,690|
|Dividend & Yield||N/A (N/A)|